More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.95B
EPS
0.65
P/E ratio
83.5
Price to sales
6.7
Dividend yield
--
Beta
1.084549
Previous close
$57.48
Today's open
$57.48
Day's range
$57.32 - $58.68
52 week range
$28.95 - $59.75
show more
CEO
Dominick Colangelo
Employees
398
Headquarters
Burlington, MA
Exchange
NASDAQ Global Market
Shares outstanding
51029770
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Stephens Annual Investment Conference at 4:30 p.m. ET (3:30 p.m. CT) on Wednesday, November 18, 2026.
GlobeNewsWire • Nov 13, 2026

Earnings Estimates Moving Higher for Vericel (VCEL): Time to Buy?
Vericel Corporation (VCEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks Investment Research • Nov 10, 2026

Vericel Q3 Earnings Call Highlights
Vericel NASDAQ: VCEL raised its full-year revenue and profitability outlook after third-quarter sales rose 26%, led by growth in its MACI cartilage repair product and a record quarter for its burn care business.
MarketBeat • Nov 6, 2026

Vericel Corporation (VCEL) Q3 2026 Earnings Call Transcript
Vericel Corporation ( VCEL ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Richard Newitter - Truist Securities, Inc., Research Division Ryan Zimmerman - BTIG, LLC, Research Division Samuil-Hrabar Gatev - Leerink Partners LLC, Research Division Mason Carrico - Stephens Inc., Research Division Presentation Operator Good day, and welcome to the Vericel Corporation Third Quarter 2026 Earnings Call.
Seeking Alpha • Nov 6, 2026

Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% to $14.2 Million Adjusted EBITDA Margin of 30% Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28% Conference Call Today at 8:30am Eastern Time
GlobeNewsWire • Nov 5, 2026

Vericel Corporation (VCEL) Beats Q3 Earnings and Revenue Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.1 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
GlobeNewsWire • Oct 22, 2026

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 16, 2026

Vericel: MACI And Regenerative Knee Cartilage
Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.
Seeking Alpha • Sep 15, 2026

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.
GlobeNewsWire • Sep 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Vericel Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.